| DB ID | MyCo_1127 |
| Title | Invasive Infections Caused by Nannizziopsis spp. Molds in Immunocompromised Patients |
| Year | 2018 |
| PMID | 29460742 |
| Fungal Diseases involved | Invasive fungal infection |
| Associated Medical Condition | None |
| Genus | Nannizziopsis |
| Species | spp. |
| Organism | Nannizziopsis spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Cerebrospinal fluid (CSF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Africa |
| Cohort | Case-patient 1 was a 63-year-old woman from France who had been treated for T-cell prolymphocytic leukemia di- agnosed in December 2014. Case-patient 2 was a 52-year-old woman from France living in Mali, who was hospitalized in Bamako in November 2016 for cough, fever, alteration of general state, and headache. |
| Cohort No. | 2 |
| Age Group | 52-63 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | BDG assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | BDG Assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
